Surrogate end points and postprogression survival in renal cell carcinoma: An analysis of first-line trials with targeted therapies

Clinical Genitourinary Cancer

Volumn 11, Issue 4, 2013, Pages 385-389

  Petrelli, Fausto ^a   Barni, Sandro ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Overall survival; Phase III trials; Postprogression survival; Progression free survival; Renal cell carcinoma; Surrogate end points; Targeted therapies

Indexed keywords

AXITINIB; BEVACIZUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER SURVIVAL; CORRELATION COEFFICIENT; DISEASE CONTROL RATE; HUMAN; KIDNEY CARCINOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTPROGRESSION SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSE RATE; REVIEW; TREATMENT RESPONSE;

OVERALL SURVIVAL; PHASE III TRIALS; POSTPROGRESSION SURVIVAL; PROGRESSION-FREE SURVIVAL; RENAL CELL CARCINOMA; SURROGATE END POINTS; TARGETED THERAPIES;

ANGIOGENESIS INHIBITORS; BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RESEARCH DESIGN; SURVIVAL; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84888016382     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.07.012     Document Type: Review

References (24)

1. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
2. B.I. Rini, S. Halabi, and J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
3. B. Escudier, J. Bellmunt, and S. Négrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
4. K. Hotta, E. Suzuki, and M. Di Maio Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer Lung Cancer 79 2013 20 26
5. K.R. Broglio, and D.A. Berry Detecting an overall survival benefit that is derived from progression-free survival J Natl Cancer Inst 101 2009 1642 1649
6. F. Petrelli, and S. Barni Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer Ann Oncol 24 2013 186 192
7. T.E. Delea, A. Khuu, and D.Y. Heng Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma Br J Cancer 107 2012 1059 1068
8. K.R. Johnson, C. Ringland, and B.J. Stokes Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis Lancet Oncol 7 2006 741 746
9. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
10. C.N. Sternberg, R.E. Hawkins, and C. Szczylik Randomized, double- blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (MRCC): final overall survival (OS) results Ann Oncol 21 suppl 8 2010 abstract LBA22
11. S. Negrier, E. Jäger, and C. Porta Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET Med Oncol 27 2010 899 906
12. B.I. Rini, S. Halabi, and J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
13. B. Escudier, A. Pluzanska, P. Koralewski AVOREN Trial investigators Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
14. G. Hudes, M. Carducci, P. Tomczak Global ARCC Trial Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
15. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
16. B.I. Rini, J. Bellmunt, and J. Clancy Randomized phase IIIb trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTERACT Ann Oncol 23 suppl 9 2012 abstract LBA21-PR
17. R. Motzer, T.E. Hutson, and J. Reeves Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the COMPARZ trial Ann Oncol 23 suppl 9 2012 abstract LBA8-PR
18. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
19. R.J. Motzer, B. Escudier, S. Oudard RECORD-1 Study Group Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
20. G. Sonpavde, T.K. Choueiri, and B. Escudier Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol 61 2012 307 316
21. G. Procopio, E. Verzoni, and R. Iacovelli Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience Expert Rev Anticancer Ther 11 2011 1631 1640
22. D.Y. Heng, W. Xie, and G.A. Bjarnason Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy Cancer 117 2011 2637 2642
23. K.M. Krajewski, M. Guo, and A.D. Van den Abbeele Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma Eur Urol 59 2011 856 862
24. N.M. Agostino, R. Gingrich, and J.J. Drabick Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature Adv Urol 2010 Pii: 687043. http://dx.doi.org/10.1155/2010/687043 Epub 2010 Jul 20